Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...

Gilead/Kite have aspirations to challenge Kymriah in paediatric ALL as well, and are currently running the phase 1/2 ZUMA-4 trial in children and adolescents with this type of blood cancer.

Kite Pharma’s share price has dived after it emerged that a patient has died from cerebral oedema while being treated with its CAR-T therapy, KTE-C19. Investors were spooked by the news ...

TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have a 78% phase transition ...

A 23-year-old man died after a nylon manja slit his throat while he was riding a motorcycle in Maharashtra's Nashik city on Tuesday, police said. The incident occurred in the Pathardi village ...

Sanofi S.A. Part Cert-1.97% €8.03M ...

OKYO Pharma (OKYO) has been notified that the CEO Gary Jacob has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a price of $1.04 per share. The company said, “We have also been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...